Company Profiles

driven by the PitchBook Platform

ARMO BioSciences

Description

Developer of immunotherapeutics. The company is a clinical-stage enterprise developing immunotherapies focused on multiple, difficult-to-treat oncology indications. Its lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. It plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors.

2012

Founded

PRIVATE

Status

11-50

Employees

Series C

Latest Deal Type

$50M

Latest Deal Amount

$100M

Total Amount Raised

Description

Developer of immunotherapeutics. The company is a clinical-stage enterprise developing immunotherapies focused on multiple, difficult-to-treat oncology indications. Its lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. It plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors.

Website:

www.armobio.com

Formerly Known As

Targenics

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Pharmaceuticals
Drug Discovery

Primary Office

575 Chesapeake Drive Redwood City, CA 94063United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore ARMO BioSciences's full profile, request a free trial.

    ARMO BioSciences Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    ARMO BioSciences Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    ARMO BioSciences Investors (9)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    CelgeneCorporationMinority000 0000000 0000
    Clough Capital PartnersMutual FundMinority000 0000000 0000
    Duff Ackerman & GoodrichPE/BuyoutMinority000 0000000 0000
    GVCorporate Venture CapitalMinority000 0000000 0000
    HBM Healthcare InvestmentsVenture CapitalMinority000 0000000 0000
    Celgene Corporation
    Clough Capital Partners Mutual Fund
    Duff Ackerman & Goodrich PE/Buyout
    GV Corporate Venture Capital
    HBM Healthcare Investments Venture Capital

    ARMO BioSciences Executive Team (4)

    NameTitleBoard
    Seat
    Contact
    Info
    Martin Oft MDCo-Founder & Vice President, Pre-Clinical & Clinical Development
    Scott Ogg Ph.DVice President, Corporate Development & Operations
    Gail Brown MDChief Medical Officer
    Peter Van Vlasselaer Ph.DChief Executive Officer, Co-Founder, Board Member & President
    Martin Oft MD Co-Founder & Vice President, Pre-Clinical & Clinical Development
    Scott Ogg Ph.D Vice President, Corporate Development & Operations
    Gail Brown MD Chief Medical Officer
    Peter Van Vlasselaer Ph.D Chief Executive Officer, Co-Founder, Board Member & President

    ARMO BioSciences Board Members (3)

    NameRepresentingRoleSinceContact
    Info
    Beth Seidenberg MDKleiner Perkins Caufield & ByersGeneral Partner000 0000
    Carl Gordon Ph.DOrbiMedFounding Partner & Co-Head of Global Private Equity000 0000
    Peter Van Vlasselaer Ph.DSelfChief Executive Officer, Co-Founder, Board Member & President000 0000
    Beth Seidenberg MD General Partner Kleiner Perkins Caufield & Byers
    Carl Gordon Ph.D Founding Partner & Co-Head of Global Private Equity OrbiMed
    Peter Van Vlasselaer Ph.D Chief Executive Officer, Co-Founder, Board Member & President Self
    Request full access to PitchBook